Protagonist Therapeutics (PTGX) Enterprise Value (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Enterprise Value of -$547.8 million for Q1 2026, up 3.45% sequentially from -$567.4 million in Q4 2025, and up 4.62% YoY from -$523.6 million in Q1 2025.
Protagonist Therapeutics (PTGX) Enterprise Value (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Enterprise Value for 12 years, with the latest figure at -$547.8 million in Q1 2026.
- Quarterly Enterprise Value rose 4.62% year-over-year to -$547.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$547.8 million (up 4.62% YoY) and the FY2025 annual result came in at -$567.4 million, down 35.44% from the prior year.
- Enterprise Value grew to -$547.8 million in Q1 2026 per PTGX's latest filing, from -$567.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$120.5 million in Q2 2022 and troughed at -$576.1 million in Q3 2025.
- A 5-year average of -$396.9 million and a median of -$341.6 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 37.47% in 2022, then plunged 160.15% in 2023.
- Over 5 years, Enterprise Value stood at -$237.3 million in 2022, then slumped by 43.94% to -$341.6 million in 2023, then declined by 22.62% to -$418.9 million in 2024, then tumbled by 35.44% to -$567.4 million in 2025, then increased by 3.45% to -$547.8 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$547.8 million, -$567.4 million, and -$576.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | -782.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -782.58 Mn |
| Mar 31, 2026 | -547.81 Mn |
| Dec 31, 2025 | -567.39 Mn |
| Sep 30, 2025 | -576.12 Mn |
| Jun 30, 2025 | -570.47 Mn |
| Mar 31, 2025 | -574.35 Mn |
| Dec 31, 2024 | -418.91 Mn |
| Sep 30, 2024 | -468.72 Mn |
| Jun 30, 2024 | -564.00 Mn |
| Mar 31, 2024 | -322.67 Mn |
| Dec 31, 2023 | -341.63 Mn |
| Sep 30, 2023 | -320.75 Mn |
| Jun 30, 2023 | -313.38 Mn |
| Mar 31, 2023 | -230.79 Mn |
| Dec 31, 2022 | -237.34 Mn |
| Sep 30, 2022 | -267.44 Mn |
| Jun 30, 2022 | -120.46 Mn |
| Mar 31, 2022 | -305.29 Mn |
| Dec 31, 2021 | -326.90 Mn |
| Sep 30, 2021 | -314.30 Mn |